Oxacillin resistant Staphlococcus aureus among HIV infected and non-infected Kenyan patients by Ouko, TT et al.
May 2010 EAST AFRICAN MEDICAL JOURNAL   179
INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA) 
strains were first detected in the early 1960s, shortly 
after methicillin came into clinical use (1) and since 
then, there has been an increase in prevalence in 
many geographic locations throughout the world 
(2). Freestanding nursing homes and other long-term 
healthcare facilities, have reported MRSA rates of 10 to 
15% (3). In Africa, studies done at Muhimbili Medical 
Hospital in Tanzania, Kenyatta National Hospital in 
Kenya and in South Africa found prevalence rates 
of MRSA at 0.4, 39.8 and 26.9% respectively (4-6). 
These prevalence variations are as a result of different 
geographical locations with varying MRSA strains 
of different virulence or colonisation properties, or 
it may reflect differences in antimicrobial utilisation 
and hospital infection control practices. Molecular 
epidemiology studies have shown that a limited 
number of MRSA strains have spread by clonal 
dissemination between different hospitals, cities, 
countries, and even continents and are now the major 
cause of hospital infections worldwide (7). 
 HIV-infected patients have an exceptional 
vulnerability to invasive bacterial infections in 
comparison to immuno-competent and HIV non-
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ABSTRACT
Background: Infections due to methicillin resistant S. aureus (MRSA) present global 
challenges to clinicians since therapeutic options are limited and suboptimal dosing 
contributes to heightened mortality and increased length of hospital stay particularly 
among the HIV infected patients. 
Objectives: To assess the prevalence and relative risk of MRSA infections in HIV 
infected patients. 
Design: Cross sectional analytical study. 
Setting: Kenya Medical Research Institute, Opportunistic Infection Laboratories in 
Nairobi.
Subjects: Four hundred and thirty six male and female patients aged one to 65 years, 
of whom 220 were HIV-infected and 216 were non-infected.
Results: There was 436 male (57.1%) and female (42.9%) respondents. The prevalence 
of MRSA was 26.3% with majority infecting the HIV infected patients (P=0.046). 
Likewise, the overall Staphylococcal infections were more common in HIV patients 
(P <0.001). The common test for MRSA oxacillin disk diffusion had a sensitivity and 
specificity of 100% and 92%. 
Conclusion: HIV is a predisposing factor to Staphylococcal infection and there are 
indications that treatment with β-lactam antibiotics may no longer be relied on as sole 
empiric therapy for several ill HIV patients whose infections may be of MRSA in origin. 
There is need for an informed choice in administration of appropriate antibiotics in 
order to minimise treatment failures due to the multidrug resistance and Vanvomycin 
intermediate S. aureus (VISA) strains. Molecular epidemiology of MRSA strains in 
understanding new and emerging trends is recommended. 
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infected patients (8). Multiple resistance to the 
commonly used antibiotics exhibited by bacterial 
strains such as MRSA, have continued to increase 
globally and present a considerable dilemma to 
clinicians, since therapeutic options are limited and sub 
optimal dosing contributes to heightened mortality and 
increased length of hospital stay particularly among the 
HIV infected patients (9). In Kenya, the antimicrobial 
regimens used in treatment of staphylococcal infections 
in HIV-infected and non-infected individuals are 
usually administered without informed choice from 
the laboratory. This practice poses serious challenges 
in the management of MRSA infections in HIV patients 
because of the reported high prevalence rate levels of 
HIV and MRSA (4,10). 
 The transitional change of MSSA to MRSA 
is mainly the result of MecA gene which encodes 
an extra penicillin-binding protein (PBP) 2a or 
PBP2’ that has decreased affinity for β-lactam 
antibiotics, thus allowing cell wall synthesis to 
continue despite inactivation of native PBPs (11) 
and is virtually resistant to all β-lactam antibiotics 
including penicillin, cephalosporin, monobactams 
and carbapenems (1,7). In the past, vancomycin 
has been considered the only agent to which MRSA 
have not developed resistance to. However, due to 
overuse of glycopeptide antibiotics, MRSA with 
reduced susceptibility to vancomycin have emerged 
as well (12). Reports on emergence of VISA in the 
USA have been noted which suggest that S. aureus 
strains are constantly evolving and full vancomycin 
resistant S. aureus (VRSA) may soon evolve leaving 
no treatment options (13). 
 Frequencies, patterns and distributions of resistant 
bacteria vary significantly with geographic regions. In 
Kenya, there is no proper epidemiological data on the 
scope and extent of MRSA infections in HIV infected 
individuals. Given the potential severity of infections 
caused by MRSA, their recent emergence in settings 
outside the hospital environment and the challenges 
in treatment and control measures, it is important that 
epidemiological studies are encouraged to provide 
baseline data on the prevalence and relative risk of 
MRSA infections among patients with and without HIV 
infection. Such data, as presented in this study, may be 
used to guide implementation of appropriate control 
measures to minimize spread of MRSA. 
MATERIALS AND METHODS
This was a cross sectional study conducted at four 
different sites: Mbagathi District Hospital and Alupe 
sub-District hospital admitting both HIV infected and 
non-infected patients, two institutions: Cottolengo 
and Thomas Barnardos in Nairobi that provide homes 
for both HIV infected and non-infected children 
respectively. The respondents were of known HIV 
status and were from either those admitted to hospital 
for a period of more than three months or drawn 
from confined institutions offering medical care with 
history of hospital admission of less than one week. 
The participants were recruited based on clinical 
signs of suspected bacterial infections. Specimens 
for culture were obtained from various sources 
depending on the symptoms and included superficial 
lesions (wound swabs), blood for suspected systemic 
deep seated infections such as septicaemia, sputum 
for suspected pneumonia and lung aspirates for 
those with severe pneumonia, CSF from suspected 
meningitis and urine for suspected cases of urinary 
tract infections. 
 Culture of the samples for the isolation of S. aureus, 
drug susceptibility and PCR for mecA gene was 
conducted at KEMRI/JICA Opportunistic Infection 
(OI) Laboratory in Nairobi. 
Culture and drug sensitivity: Culture of the specimens 
was performed on mannitol salt and sheep blood agar 
media (SBA) and incubated aerobically at 35°C for 
18 to 24 hours. The colonies appearing yellowish in 
mannitol medium with β-haemolysis on SBA was gram 
stained and subjected to coagulase test. Confirmation 
of S. aureus was done using analytical profile index 
(API Staph, Biomerieux) (14). The confirmed S. aureus 
isolates were subjected to antimicrobial susceptibility 
testing against oxacillin (OX), vancomycin (VAN), 
gentamycin (GEN), amoxicillin clavulanic acid 
(AMC), chloramphenicol (CHL), erythromycin 
(ERY), tetracycline (TET), cefotaxime (CTX), and 
sulfamethoxazole/trimethoprim (SXT) using disk 
diffusion for immediate patient treatment and 
management before being pooled for minimum 
inhibitory concentration (MIC) testing using E-test 
and interpreted as per the Clinical and Laboratory 
Standards Institute (15). The resistance rate was 
calculated as the total number of isolates minus 
those sensitive. Multi-drug resistance was defined as 
resistance to oxacillin and or cefotaxime plus three 
or more of the drugs (16,17). 
Determination of mecA gene by PCR: The test organism 
was grown on Brain Heart Infusion broth (BHI) 
overnight then centrifuged at 10,000 rpm for five 
minutes at room temperature. The supernatant was 
discarded and the sediment cells re-suspended in 
1 ml of TE buffer and vortexed. After this, 200µl 
was transferred to a new sterile tube and boiled 
for 30 minutes to release the DNA. The suspension 
was centrifuged at 15,000 rpm. for ten minutes and 
the supernatant used as template DNA for PCR. 
PuRe Taq Ready-To- Go PCR beads (Amersham 
biosciences) with a total reaction volume of 25µl, was 
May 2010 EAST AFRICAN MEDICAL JOURNAL   181
used in the PCR run using the following primer set: 
F’GGTGGTTACAACGTTACAAG-3”= 02µl; R- 5’GCA
TTGTAGCTAGCCATTCC3’= 0.2µl; the template DNA 
= 1.0µl; with sterile distilled water of 23.6µl. The PCR 
conditions were set as follows: initial denaturation 
step of three minute at 94°C followed by a further 30-
second of denaturation at 94°C; annealing step at 55°C 
for 30-seconds and extension at 71°C for 30-seconds 
for 35 cycles. The PCR products were separated by 
gel electrophoresis in 1.5% agarose (TAKARA) and 
visualised under ultraviolet light against a standard 
molecular base pair (1kb) ladder (18). 
Data analysis:  Demographic characteristics of the 
respondents, prevalence of S. aureus and antibiotic 
responses were analysed using EPI INFO 2000 
(CDC, ATLANTA). Analysis of variance on multiple 
proportions was performed using Chi-square test. 
RESULTS
Demographic characteristics of respondents: A total of 436 
patients, 57.1% males and 42.9% females clinically 
suspected to have a bacterial infection were recruited 
from four study sites: Mbagathi 150 (34.4%), Alupe sub 
District hospital 50 (11.5%), Cottolengo 76 (17.4%) and 
Thomas Benardos 160 (36.7%). Out of the respondents, 
220 (50.5%) were HIV-infected while 216 (49.5%) 
were HIV non-infected (Table 1). The number of HIV 
infected and non-infected children were 76 and 160 
respectively verses 144 and 56 adults respectively. 
The age of the patients studied ranged from one to 
sixty five years with majority of the patients (70%) 
falling below 30 years.
Prevalence of Staphylococcus aureus: The prevalence of 
staphylococcal infections among the respondents was 
118/436 (27.1%). The MRSA prevalence accounted 
for 31/118 (26.3%) with majority of the strains being 
recovered from cases of superficial lesions 18/118 
(15.3%) and systemic deep seated infections 118/13 
(11%). The HIV-infected group were more likely to 
be infected with staphylococcal compared to the HIV 
non-infected P < 0.001 with an MRSA rate among the 
HIV of 9.6% as compared to the HIV non-infected 
4.6%, P=0.046 (Table 1). 
 The MRSA from males and females was 3.9% 
and 3.2% respectively with a prevalence variation 
ranging from 4/50 (8%) in Alupe to 10/76 (13.2%) 
in Cottolengo in the HIV positive group and 3.6% 
in Mbagathi to 5% in Thomas Benardos in the HIV 
negative group. Five strains from HIV positive 
patients exhibited vancomycin intermediate S. aureus 
resistance (VISA) from Alupe sub-District and 
Mbagathi District hospitals (Table 2). 
Table 1
Staphylococcus aureus strains isolation by HIV status
 
 HIV positive (n=220) HIV- Negative (n=216) P-value 
 No.     (%) No.     (%) 
S. aureus isolates  75      34.1  43      19.4  P<0.001 
MRSA  21       9.6  10       4.6  P=0.046 
Table 2
Number of S. aureus isolates by HIV and institutions
Institution No. of   No. of MSSA  No. of MRSA HIV serostatus  
 respondents isolates  isolates 
Cottolengo  76 24 10 HIV positive children 
Alupe sub-District hospital  50 13 ***4 HIV positive adults 
Mbagathi District hospital 94 17 **7 HIV positive adults 
Mbagathi District hospital  56 11 2 HIV negative adults 
Thomas Benardos 160  22 8 HIV negative children 
Total  436  87 31
***Three of the strains were vancomycin intermediate S. aureus (VISA) 
** Two of the strains were VISA 
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MRSA detection: Of the 118 isolates tested for mecA 
gene, 31 were positive. The correlation between 
phenotypic test results and the mecA gene showed 
38 MRSA by oxacillin disk diffusion and 40 MRSA by 
cefotaxime disk diffusion as the only common two 
tests used for the detection of MRSA. 
Antibiotic susceptibility of the isolates: The S. aureus isolates 
were found to be highly sensitive to vancomycin with 
4.2% of the 118 S. aureus isolates exhibiting intermediate 
resistance having an MIC of >8 µg/ml. The second 
most effective drug was AMC with a sensitivity of 
76.9% followed by CHL at 73.5%. The sensitivity rate 
to OX and CTX were both at  70.3% with GEN and 
TET at 60.5% and 54.8% respectively. Low sensitivity 
rates of the isolates were seen in SXT 42.7% and ERY 
at 41.1% (Table 3). It was noted that 23 (19.5%) of the 
isolates were resistant to OX plus three or more of the 
drugs tested of which 21 were MRSA. Two of the strains 
were mecA gene negative and were resistant to four of 
the drugs including OX. Of the 21 MRSA, six strains 
were resistant to seven drugs, six to six drugs, six to 
five drugs and three to four drugs while the five strains 
which exhibited vancomycin intermediate resistance 
were from the 74 strains from HIV 6.8% (Table 3) 
with an MIC of 8 µg/ml. The drug susceptibility test 
profile was compared and found to have no statistical 
difference in the profile (Table 3). 
Table 3
Statistical comparison of antibiogram by HIV status
Drug  HIV positive  HIV negative  X2 - test 
 No.  % sensitivity  No.  % sensitivity  P-value 
Oxacillin  75  68.0  43  74.4  0.46 
Cefotaxime  75  66.7  43  76.7  0.26 
Vancomycin  74  93.2  43  100  0.08 
Amoxicillin-clavulanic acid  74  75.7  43  79.1  0.68 
Trimethoprin-Sulphamethoxazole  75  49.3  42  31.0  0.055 
Erythromycin  69  43.5  43  37.2  0.51 
Chloramphenicol  74  71.6  43  76.7  0.55 
Tetracycline  73  56.2  42  52.4  0.69 
Gentamycin  72  62.5  42  57.1  0.59
Figure 1
Gel photomicrograph of mecA gene PCR product showing well number 1 with 1000 bp ladder; 2, 3, 7-10 and 12 are 
negative clinical isolates for mecA; 4 is a positive mecA (S. aureus A TCC 33592); 5, 6 and 11 are positive clinical 
isolates for mecA.; well 12 negative control for mecA gene (S. aureus ATCC 25923)
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DISCUSSION
This study showed a prevalence rate of MRSA at 
26.3%, which from an epidemiological point of view 
is considered high since it has been shown that MRSA 
prevalence rate of greater than 25% to be high and 
indicates poor national infection control practices 
(19). The isolates in this study are considered hospital 
based (HA-MRSA) because all the respondents were 
either admission cases for a period of more than three 
months or drawn from confined institutions offering 
medical care with history of hospital admission of 
less than one week. This differs from community 
acquired strains type (CA-MRSA) where the source 
has to be from outside healthcare settings with no 
prior history of hospitalisation within the preceding 
two years (20). 
 Although the MRSA prevalence finding 
compares well with studies observed in South Africa 
26.9% (6) and 29% quoted by the National Nosocomial 
Infection Surveillance System (NNISS) in USA (21), 
higher prevalence rate (39.8%) was reported in Kenya, 
in by Omar at al (4) which could have probably been 
attributed to high sensitivity of oxacillin disk diffusion 
test system used by the author for MRSA detection, 
thereby picking and accounting for strains of S. aureus 
which were simply over-expressing β-lactamase 
enzymes and were not necessarily MRSA as have 
been argued in other studies (6,22,23). 
 Several resistance surveillance studies have been 
conducted which provide comparable and validated 
results on the status of MRSA. In Europe, surveillance 
studies including 27 countries across Europe found 
an overall 20% MRSA prevalence with the highest 
proportion in Southern and parts of Western Europe 
and lowest proportion (5%) in Northern Europe (24). 
Reports from Nigeria, Kenya and Cameroon, have 
quoted rates between 21% to 30%, and below 10% 
in Tunisia, Malta, Tanzania and Algeria (5,25). This 
variability, besides the use of different test systems for 
MRSA detection, could as well have been attributed to 
geographic variation of MRSA strains with different 
virulence properties and or may reflect differences 
in antimicrobial utilisation and infection control 
practices. 
 One of the resistance mechanisms of S. aureus is as 
a result of chromosomally localised MecA gene which 
codes for an additional penicillin binding protein 
PBP 2’ or PBP2a that has low affinity for beta lactam 
antibiotics and substitutes functions of the native 
PBP during cell wall synthesis. The transcription of 
the gene is usually induced through exposure to beta 
lactam drugs (14) and since HIV positive patients are 
more exposed to such drugs during opportunistic 
infection management, it may perhaps explain why 
the chances of contracting staphylococcal infections of 
MRSA origin in HIV is twice higher (OR = 2.174) as 
compared to the HIV negative group. 
 Antimicrobial resistance among bacterial 
pathogens is a significant problem worldwide with 
consequences including increased hospital stay, 
medical costs, morbidity and mortality of patients 
(26). The observed 19.5% multi drug resistant strains 
and the 6.8% VISA found in the HIV positive cases 
is worrying and are more likely to have serious 
implications on the treatment and healthcare 
management of HIV patients. The multi-drug 
resistance level shown in this study and the expected 
high cost and delay involved in offering appropriate 
treatment for diseases of multi-drug resistance origin 
(27) reflect an increase in mortality particularly among 
the 11% patients with deep seated and systemic cases. 
Besides, there is a likelihood danger of spread of these 
strains (HA-MRSA) to the community and an increase 
in morbidity due to lack of proper infection control 
measures in most public hospitals which control the 
largest hospital attendance in Kenya. 
 Several risk factors associated with MRSA 
infections have been described (28). The study showed 
a higher isolation rate and a significant difference in 
the prevalence of staphylococcal infections in the HIV 
infected group (p< 0.001) and those strains of MRSA 
in origin (p= 0.046). A study done in San Diego, 
California in 2005, showed an annual incidence of 
staphylococcal infections among the HIV as eight-fold 
higher than in HIV non-infected (29). The difference 
may probably be due to the vulnerability of HIV 
patients to this opportunistic pathogen (MRSA) 
which normally resides on human skin and picks 
up when the right opportunity such as cancer drugs 
and diseases which lowers immunity strikes. Besides, 
it could also be related to the low level of infection 
control practices by healthcare management in these 
institutions. 
 Bacterial resistance is a threat to antimicrobial 
treatment of infections in the 21st century, (30). 
S. aureus has always been difficult to treat for the 
numerous infections that are caused by this organism 
at community and hospital environments. The 
introduction of new classes of antimicrobial agents is 
usually followed by the emergence of resistant forms 
of this pathogen (31,32). As such, surveillance on 
the antimicrobial susceptibility patterns of S. aureus 
is of utmost importance in understanding new and 
emerging resistance trends and more particularly, in 
the management of opportunistic infections in the 
HIV infected patients. 
 The high MRSA prevalence in the study indicates 
that there may be very few treatment options left for 
Staphylococcal infections since all beta lactam drugs as 
first line treatment can no longer be used effectively. 
This finding agrees with the 26.9% reported in South 
Africa (6). 
 Although there was no significance drug 
resistance pattern difference among the two groups, 
the 6.8% vancomycin intermediate resistant in 
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HIV positive adults suggests serious public health 
implications in treatment of these patients whose 
immunity is low and may not afford the cost of the 
limited treatment options available. 
 Antimicrobial resistance among bacterial 
pathogens is a significant problem in many countries 
with severe consequences including increased 
medical costs, morbidity and mortality of patients 
(26). Since the emergence of S. aureus strains with 
resistance to penicillin and methicillin (1,33) it has 
become a well-known aetiologic agent with a wide 
variety of infections that are difficult to treat. The 
resistance mechanism to S. aureus exhibits mainly 
in three forms, the one mediated by blaZ, the gene 
that encodes β-lactamase. This predominantly extra 
cellular enzyme, synthesised when staphylococci are 
exposed to β-lactam antibiotics, hydrolyzes the β-
lactam ring, rendering the β-lactam inactive. blaZ is 
under the control of two adjacent regulatory genes, 
the antirepressor blaR1 and the repressor blal (34). 
Recent studies have demonstrated that the signalling 
pathway responsible for β- lactamase synthesis 
requires sequential cleavage of the regulatory proteins 
BlaR1 and Blal. 
 Following exposure to β-lactams, BlaR1, a 
transmembrane sensor-transducer, cleaves. It had 
been hypothesised that the cleaved protein functions 
as a protease that cleaves the repressor Blal, directly 
or indirectly and allows blaZ to synthesize enzyme 
itself (35,36). 
 Another resistance mechanism is the presence of 
the chromosomally localised mecA gene which codes 
for an additional PBP, termed PBP2' or PBP2a that has 
low affinity for β-lactam antibiotics and substitutes 
for the native PBPs during cell wall synthesis when 
they are inhibited by β-lactams (14). Transcription 
of the mecA gene is induced in some isolates by β-
lactams, and such induction is regulated by Mecl and 
MecR1, a repressor and a signal-transducing protein, 
respectively (14). The mecl and mecR1 genes, when 
present, are carried beside mecA on the SCCmec 
element (37-39). Cross-regulation by Blal and BlaR1 
of mecA transcription also occurs, encoded by blal 
and blaR1 genes carried on the β-lactamase plasmid 
along with blaZ (14). 
 Until now, the background PBPs in S. aureus 
have been assumed to be constitutively expressed. 
Recently, constitutive pbpB transcription has been 
studied (40), though the factors that control or induce 
pbpB gene expression have not yet been explored. 
Lastly, there is the borderline resistance, which is a 
low-level type of resistance to methicillin exhibited 
by strains which neither produce mecA gene nor over 
express β-lactamase enzyme. 
 Besides the high level of oxacillin resistance 
attained through acquisition of the mecA gene, 
another resistance mechanism, such as over 
expression of betalactamase, may have accounted for 
the 7/118 (6%) oxacillin resistance in S. aureus which 
were mecA gene negative as have been indicated 
elsewhere (23). 
 The mechanism(s) responsible for mecA transfer 
is not known, but evidence supports horizontal 
transfer of mec DNA between staphylococcal species 
and of the mecA gene between different gram-positive 
genera (41). 
In conclusion, HIV is a predisposing factor to MRSA 
infections and the multi-drug resistant MRSA and 
VISA is threatening to return us to the era that 
preceded the development of antibiotics. Even 
though there was no antibiogram pattern difference 
among the isolates from both HIV and non-HIV 
positive groups, there are indications that treatment 
with β-lactam antibiotics may no longer be relied on 
as sole empiric therapy for several ill HIV patients 
whose infections may be of staphylococcal and more 
so MRSA in origin MRSA prevalence is best predicted 
by use of PCR as the gold standard for mecA gene in 
epidemiological studies, however, oxacillin is more 
suitable for immediate treatment and management of 
Staphylococcal diseases. The high MRSA prevalence, 
the multi-drug resistance and the emerging strains of 
VISA call for an informed choice in administration of 
appropriate antibiotics. Molecular epidemiology of 
MRSA strains in understanding new and emerging 
trends is recommended. 
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